|
【结 构 式】 
|
【分子编号】28908 【品名】L-Threonine; (2R,3S)-2-amino-3-hydroxybutyric acid 【CA登记号】632-20-2 |
【 分 子 式 】C4H9NO3 【 分 子 量 】119.1204 【元素组成】C 40.33% H 7.62% N 11.76% O 40.29% |
合成路线1
该中间体在本合成路线中的序号：(II)The condensation of 4-ethyl-2,3-dioxo-1-piperazinecarbonyl chloride (I) with threonine (II) in methylene chloride gives alpha-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-beta-hydroxybutyric acid (III), which is then condensed with diphenylmethyl 7-beta-amino-3-[(1-methyltetrazol-5-yl)thiometnyl)-Delta3-cephem-4-carboxylate (IV) by means of ethyl chloroformate and N-methyl morpholine yielding diphenylmethyl 7-beta-[alpha-(4-ethyl-2,3-dioxo-1-piperazi-necarboxamido)-beta-hydroxybutyramido]-3-(11-methyltetrazol-5-yl)thiomethyl]-Delta3-cephem-4-carboxylate (V). The methoxylation of (V) with lithium methoxide-methylene chloride THF affords diphenyl methyl 7-beta-[alpha-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-beta-hydroxybutyramido]-7-alpha-methoxy-3-[(1-methyltetrazol-5-yl)thiamethyl-Delta3-cephem-4-carboxylate (VI), which is finally hydrolyzed with trifluoroacetic acid, and treated with NaHCO3 to obtain the sodium salt.
| 【1】 Saikawa, I.; et al. (Toyama Chemical Co., Ltd.); Novel 7alpha-methoxycephalosporins and process for producing the same. FR 2455051; GB 2048241; JP 80141.491; JP 8125188; US 4263292 . |
| 【2】 Burnie, J.; Serradell, M.N.; Castaner, J.; Cefbuperazone Sodium. Drugs Fut 1985, 10, 1, 14. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 24305 | 4-ethyl-2,3-dioxo-1-piperazinecarbonyl chloride | 59703-00-3 | C7H9ClN2O3 | 详情 | 详情 |
| (II) | 28908 | L-Threonine; (2R,3S)-2-amino-3-hydroxybutyric acid | 632-20-2 | C4H9NO3 | 详情 | 详情 |
| (III) | 28909 | (2R,3S)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-3-hydroxybutyric acid | C11H17N3O6 | 详情 | 详情 | |
| (IV) | 28910 | benzhydryl (6R,7R)-7-amino-3-[[(1-methyl-1H-1,2,3,4-tetraazol-5-yl)sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | C23H22N6O3S2 | 详情 | 详情 | |
| (V) | 28911 | benzhydryl (6R,7R)-7-[((2R,3S)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-3-hydroxybutanoyl)amino]-3-[[(1-methyl-1H-1,2,3,4-tetraazol-5-yl)sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | C34H37N9O8S2 | 详情 | 详情 | |
| (VI) | 28912 | benzhydryl (6R,7S)-7-[((2R,3S)-2-[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]-3-hydroxybutanoyl)amino]-7-methoxy-3-[[(1-methyl-1H-1,2,3,4-tetraazol-5-yl)sulfanyl]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate | C35H39N9O9S2 | 详情 | 详情 |
合成路线2
该中间体在本合成路线中的序号：(I)D-Threonine (I) was esterified by means of thionyl chloride in methanol, and the resultant amino ester (II) was subsequently acylated with 3,5-dinitrobenzoyl chloride (III) to afford amide (IV). Conversion of (IV) to the acetoacetate ester (VI) was effected by reaction with the diketene precursor 2,2,6-trimethyl-4H-1,3-dioxin-4-one (V) in boiling xylene. Treatment of keto ester (V) with ammonia in the presence of p-toluenesulfonic acid produced the aminocrotonate ester (VI). Dihydropyridine (IXa-b) was then obtained as a diastereomeric mixture by a modified Hantzsh condensation between enamine (VI), 2-trifluoromethylbenzaldehyde (VII) and nitroacetone. After chromatographic separation of the isomers, the chiral auxiliary group was removed by methanolysis in the presence of DBU. The desired (+)-(S)-dihydropyridinecarboxylic acid (X) was finally converted to the nitrooxyethyl ester by reaction with 2-bromoethyl nitrate (XI).
| 【1】 Shan, R.; Knaus, E.E.; Howlett, S.E.; Syntheses, calcium channel agonist-antagonist modulation activities, nitric oxide release, and voltage-clamp studies of 2-nitrooxyethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate enantiomers. J Med Chem 2002, 45, 4, 955. |
| 【2】 Knaus, E.E.; Shan, R.; The design of (-)-(S)-nitrooxyethyl 1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)pyridine-5-carboxylate: A cardioselective positive inotropic derivative of Bay K 8644. Bioorg Med Chem Lett 1999, 9, 17, 2613. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (VIIII) | 30332 | 2-(trifluoromethyl)benzaldehyde | 447-61-0 | C8H5F3O | 详情 | 详情 |
| (IXa) | 59607 | (1S,2R)-2-[(3,5-dinitrobenzoyl)amino]-3-methoxy-1-methyl-3-oxopropyl (4S)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydro-3-pyridinecarboxylate | C27H24F3N5O11 | 详情 | 详情 | |
| (IXb) | 59608 | (1S,2R)-2-[(3,5-dinitrobenzoyl)amino]-3-methoxy-1-methyl-3-oxopropyl (4R)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydro-3-pyridinecarboxylate | C27H24F3N5O11 | 详情 | 详情 | |
| (I) | 28908 | L-Threonine; (2R,3S)-2-amino-3-hydroxybutyric acid | 632-20-2 | C4H9NO3 | 详情 | 详情 |
| (II) | 42026 | methyl (2S,3R)-2-amino-3-hydroxybutanoate | C5H11NO3 | 详情 | 详情 | |
| (III) | 12053 | 3,5-Dinitrobenzoyl chloride | 99-33-2 | C7H3ClN2O5 | 详情 | 详情 |
| (IV) | 59604 | methyl (2R,3S)-2-[(3,5-dinitrobenzoyl)amino]-3-hydroxybutanoate | C12H13N3O8 | 详情 | 详情 | |
| (V) | 13327 | 2,2,6-Trimethyl-4H-1,3-dioxin-4-one；2,2,6-trimethyl-1,3-dioxin-4-one；2,2,6-trimethyl-m-Dioxin-4-one;3-(1-hydroxy-1-methylethoxy)-d-lactone Crotonicacid | 5394-63-8 | C7H10O3 | 详情 | 详情 |
| (VI) | 59605 | methyl (2R,3S)-3-(acetoacetyloxy)-2-[(3,5-dinitrobenzoyl)amino]butanoate | C16H17N3O10 | 详情 | 详情 | |
| (VII) | 59606 | (1S,2R)-2-[(3,5-dinitrobenzoyl)amino]-3-methoxy-1-methyl-3-oxopropyl (E)-3-amino-2-butenoate | C16H18N4O9 | 详情 | 详情 | |
| (X) | 59609 | (4S)-2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydro-3-pyridinecarboxylic acid | C15H13F3N2O4 | 详情 | 详情 | |
| (XI) | 59610 | 1-bromo-2-(nitrooxy)ethane | C2H4BrNO3 | 详情 | 详情 |
合成路线3
该中间体在本合成路线中的序号：(I)The title zinc complex is prepared by adding ZnSO4 to an aqueous solution of the lithium salt of L-threonine.
| 【1】 Sakurai, H.; Yanagihara, N.; Suzuki, Y.; Ueda, E.; Kojima, Y.; Yoshikawa, Y.; New insulinomimetic zinc(II) complexes of alpha-amino acids and their derivatives with Zn(N2O2) coordination mode. Chem Pharm Bull 2001, 49, 5, 652. |
| 【2】 Sakurai, H.; Kojima, Y. (Japan Science and Technology Corp.); Blood glucose lowering agents containing zinc(II) organic complex. EP 1256342; JP 2001220348; WO 0139769 . |